Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
BMC Cancer. 2010 Jan 25;10:21. doi: 10.1186/1471-2407-10-21.
S100 calcium binding protein A8 (S100A8) has been implicated as a prognostic indicator in several types of cancer. However, previous studies are limited in their ability to predict the clinical behavior of the cancer. Here, we sought to identify a molecular signature based on S100A8 expression and to assess its usefulness as a prognostic indicator of disease progression in non-muscle invasive bladder cancer (NMIBC).
We used 103 primary NMIBC specimens for microarray gene expression profiling. The median follow-up period for all patients was 57.6 months (range: 3.2 to 137.0 months). Various statistical methods, including the leave-one-out cross validation method, were applied to identify a gene expression signature able to predict the likelihood of progression. The prognostic value of the gene expression signature was validated in an independent cohort (n = 302).
Kaplan-Meier estimates revealed significant differences in disease progression associated with the expression signature of S100A8-correlated genes (log-rank test, P < 0.001). Multivariate Cox regression analysis revealed that the expression signature of S100A8-correlated genes was a strong predictor of disease progression (hazard ratio = 15.225, 95% confidence interval = 1.746 to 133.52, P = 0.014). We validated our results in an independent cohort and confirmed that this signature produced consistent prediction patterns. Finally, gene network analyses of the signature revealed that S100A8, IL1B, and S100A9 could be important mediators of the progression of NMIBC.
The prognostic molecular signature defined by S100A8-correlated genes represents a promising diagnostic tool for the identification of NMIBC patients that have a high risk of progression to muscle invasive bladder cancer.
S100 钙结合蛋白 A8(S100A8)已被认为是几种类型癌症的预后指标。然而,以前的研究在预测癌症的临床行为方面能力有限。在这里,我们试图确定基于 S100A8 表达的分子特征,并评估其作为非肌肉浸润性膀胱癌(NMIBC)疾病进展的预后指标的有用性。
我们使用 103 个原发性 NMIBC 标本进行微阵列基因表达谱分析。所有患者的中位随访时间为 57.6 个月(范围:3.2 至 137.0 个月)。应用各种统计方法,包括留一法交叉验证法,以确定能够预测进展可能性的基因表达特征。在独立队列(n = 302)中验证了基因表达特征的预后价值。
Kaplan-Meier 估计显示,S100A8 相关基因表达特征与疾病进展相关存在显著差异(对数秩检验,P < 0.001)。多变量 Cox 回归分析显示,S100A8 相关基因表达特征是疾病进展的强有力预测因子(危险比= 15.225,95%置信区间= 1.746 至 133.52,P = 0.014)。我们在独立队列中验证了我们的结果,并证实该特征产生了一致的预测模式。最后,该特征的基因网络分析表明,S100A8、IL1B 和 S100A9 可能是 NMIBC 进展的重要介质。
由 S100A8 相关基因定义的预后分子特征代表了一种有前途的诊断工具,可用于识别具有向肌肉浸润性膀胱癌进展高风险的 NMIBC 患者。